New acid blocker may beat standard treatment for stomach bug
NCT ID NCT07165444
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study compares two types of acid-reducing medications—vonoprazan (a newer drug) and rabeprazole (a standard drug)—when used with bismuth and two antibiotics to treat H. pylori infection. About 320 adults with confirmed H. pylori who have not been treated before will receive one of the two 10-day regimens. The goal is to see which combination eradicates the infection better, with fewer side effects and easier adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POTASSIUM-COMPETITIVE ACID BLOCKER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tanta University
RECRUITINGTanta, El-Gharbia, 31527, Egypt
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vonoprazan (a potassium-competitive acid blocker) and rabeprazole (a proton pump inhibitor), both combined with bismuth, metronidazole, and tetracycline
What this could lead to
If successful, this could show that vonoprazan-based therapy is more effective or better tolerated than standard PPI-based therapy for eradicating H. pylori.
What could go wrong
This is a relatively small, single-center trial with no blinding, so results may not apply broadly. The drugs can cause side effects like nausea or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.